Novo's full results for Wegovy in children ages 6 to under 12 with obesity are a meaningful step. The company reported that the injection, given alongside lifestyle changes such as a reduced-calorie diet and more physical activity, lowered body mass index by an estimated 19.7 percentage points compared with placebo at 68 weeks among children who stayed on treatment. Even when the study included every child, including those who stopped treatment, the estimated reduction was 16.2 percentage points more than placebo. Those are substantial figures for a group that, as the report notes, has had few treatment options.

The need is real. The report says that 85% of the children started with moderate to severe obesity and that nearly half already had at least one obesity-related complication, such as high blood pressure, high cholesterol or sleep apnea. Novo also said more than 40% of treated children were no longer classified as having obesity after 68 weeks, assuming they stayed on treatment. Dr. Andrea Traina, Novo's medical director lead of obesity, framed the goal as controlling the disease while children are still young and at high risk of accelerated progression. That framing is persuasive, because the World Obesity Federation's projection of 228 million affected children and teens by 2040 shows the scale of the problem.

Still, the enthusiasm should be measured. The company's strongest numbers assume patients stayed on treatment, and the study included only 167 children. Novo said safety and tolerability were consistent with adult trials and that it saw no safety concerns related to growth or pubertal development, but a two-year study cannot show what happens as children become adults. Traina herself acknowledged that the question of whether earlier treatment changes the long-term trajectory remains an evidence gap.

What should happen next is clear. Regulators weighing a pediatric indication should look closely at the full trial data, including the results for children who discontinued treatment, rather than only the most favorable estimate. Researchers should follow these children for longer, and should study how treatment and maintenance work as they move through adolescence. Families and clinicians need that information before treating an 6-year-old as a long-term patient. The results are encouraging. They are not yet enough to settle what a lifetime of treatment should look like.